Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia

scientific article

Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1182/BLOOD-2012-09-458265
P3181OpenCitations bibliographic resource ID2487626
P932PMC publication ID3578955
P698PubMed publication ID23243274

P50authorRaúl RabadánQ7296181
Riccardo Dalla-FaveraQ30119384
Laura PasqualucciQ30303485
Gianluca GaidanoQ30303486
Silvia RasiQ30303488
Francesco ForconiQ30303490
Valeria SpinaQ30303495
Valter GatteiQ30303512
Francesca Maria RossiQ64785039
Robin FoàQ66385416
Pietro BulianQ87269929
Davide RossiQ89878155
Alessio BruscagginQ114336632
Carmela CiardulloQ114336633
Clara DeambrogiQ114336634
Roberto MarascaQ38326950
Francesco BertoniQ40033742
Michele Dal BoQ42703041
Josep NomdedeuQ50238034
Hossein KhiabanianQ55167918
Giovanni Del PoetaQ56950902
P2093author name stringLuca Laurenti
Sara Monti
Roberto Serra
P2860cites workDetectable clonal mosaicism and its relationship to aging and cancerQ23916196
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upQ27851444
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationQ27851655
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaQ27851685
Genomic aberrations and survival in chronic lymphocytic leukemiaQ28141442
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemiaQ28255147
Detectable clonal mosaicism from birth to old age and its relationship to cancerQ28385149
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessQ29013141
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaQ29614659
Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.Q33638819
Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survivalQ80709731
Chronic lymphocytic leukaemiaQ80932425
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotypingQ81099032
Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patientsQ84537035
SF3B1 and other novel cancer genes in chronic lymphocytic leukemiaQ34093678
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemiaQ34402999
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemiaQ35143490
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemiaQ35220403
NOTCH1 mutations in CLL associated with trisomy 12.Q35669190
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLLQ35794466
Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemiaQ36135185
Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemiaQ36421804
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemiaQ36462375
Tree-structured prediction for censored survival data and the Cox modelQ36701892
Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34Q36790673
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemiaQ36843780
Risk categories and refractory CLL in the era of chemoimmunotherapyQ37141887
Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical managementQ37552813
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaQ37980658
Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patternsQ39564847
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation.Q51609722
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.Q52621343
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia.Q53596463
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.Q55035699
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLLQ58041997
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectcell biologyQ7141
leukemiaQ29496
lymphocyteQ715347
chronic lymphocytic leukemiaQ1088156
P304page(s)1403-12
P577publication date2013-02-21
P1433published inBloodQ885070
P1476titleIntegrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
P478volume121

Reverse relations

cites work (P2860)
Q90262439"Immuno-flowFISH" for the Assessment of Cytogenetic Abnormalities in Chronic Lymphocytic Leukemia
Q5804169414q deletions are associated with trisomy 12,NOTCH1mutations and unmutatedIGHVgenes in chronic lymphocytic leukemia and small lymphocytic lymphoma
Q392662952016 WHO Classification update-What's new in lymphoid neoplasms
Q50784932A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact.
Q35859176A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia.
Q35984259A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia
Q58041425A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
Q90466691A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
Q52897018A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.
Q30768193ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Q38798801Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas
Q64246205Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience
Q33709543An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
Q31096565An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
Q48736600Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI).
Q89823528B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making
Q38185363B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies
Q89090793B-cell receptor stereotypy and chronic lymphocytic leukaemia
Q36825397BIRC3 alterations in chronic and B-cell acute lymphocytic leukemia patients
Q33409149Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Q51587472Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
Q40784167CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Q33862792Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
Q30685440Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data
Q50562319Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.
Q37615541Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia
Q26775986Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist
Q56270980Chronic lymphocytic leukaemia
Q39263974Chronic lymphocytic leukaemia genomics and the precision medicine era.
Q91666607Chronic lymphocytic leukaemia: from genetics to treatment
Q38675358Chronic lymphocytic leukemia (CLL)-Then and now.
Q57034197Chronic lymphocytic leukemia treatment algorithm 2018
Q36826893Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015
Q38708220Chronic lymphocytic leukemia: Time to go past genomics?
Q26752467Chronic lymphocytic leukemia: a clinical review including Korean cohorts
Q36998431Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics
Q38663689Clinical Impact of the 2016 Update to the WHO Lymphoma Classification
Q38744632Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia
Q42711622Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
Q37618663Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?
Q27027493Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond
Q33595764Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
Q48326934Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
Q26830955Clinical implications of the molecular genetics of chronic lymphocytic leukemia
Q89518987Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial
Q36420752Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
Q98733440Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
Q54731667Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.
Q38262761Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression
Q27027655Clonal evolution in hematological malignancies and therapeutic implications
Q42330187Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
Q42291852Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
Q85738481CpG Oligonucleotide and Interleukin 2 stimulation enables higher cytogenetic abnormality detection rates than 12-o-tetradecanolyphorbol-13-acetate in Asian patients with B-cell chronic lymphocytic leukemia (B-CLL)
Q85733304De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia
Q26823586Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution
Q35407650Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
Q34418874Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Q92158068Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations
Q91212018Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors
Q33774491Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood
Q33804706Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia
Q92964830Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia
Q37699259Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia
Q40455172EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Q39039713Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: implication for therapy
Q93081398Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
Q58585095Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials
Q38232481Evolving understanding of the CLL genome
Q33364071Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle.
Q37260520Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
Q50621489FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia.
Q64092443First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Q90427376Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature
Q35741703Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans
Q48307279Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
Q48503863Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients.
Q38819164Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Q33744997Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go
Q38669131Genetic landscape and deregulated pathways in B-cell lymphoid malignancies
Q37697850Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness
Q37649648Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients
Q28087672Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Q52714558Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers.
Q46444068High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications
Q54348577How I treat patients with relapsed chronic lymphocytic leukaemia.
Q37417412Hsa-miR-15a and Hsa-miR-16-1 expression is not related to proliferation centers abundance and other prognostic factors in chronic lymphocytic leukemia
Q38920650Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells
Q50639003IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.
Q89663745IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
Q38115229IX. Chronic lymphocytic leukaemia: new genetic markers as prognostic factors
Q33424543Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia
Q41485437Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia.
Q53147192IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Q49864609Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia
Q61799313Immunochemotherapy for Richter syndrome: current insights
Q28655983Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols
Q33904307Increased oxidative damage associated with unfavorable cytogenetic subgroups in chronic lymphocytic leukemia.
Q42923891Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
Q28067817Integrative systems medicine approaches to identify molecular targets in lymphoid malignancies
Q48138435Intratumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia.
Q34997508Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia
Q55644886Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Q36884141Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease
Q87141220MYC network mutations in high-risk chronic lymphocytic leukaemia
Q92740078Machine learning can identify newly diagnosed patients with CLL at high risk of infection
Q52675362Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Q49692075Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia
Q90292627Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Q33913537Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
Q93349257Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications
Q86483631Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis
Q38424403Molecular deregulation of signaling in lymphoid tumors
Q93603004Monoclonal B-cell lymphocytosis
Q88633752Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
Q61772114Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group
Q39714436Mutations driving CLL and their evolution in progression and relapse
Q38724344Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22.
Q64077384Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia
Q55668973NOTCH1 Aberrations in Chronic Lymphocytic Leukemia.
Q47945189NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.
Q52931736NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.
Q54345184NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Q52648282NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Q64271736NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia
Q51093052NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.
Q47616548Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukemia cells from apoptosis
Q37747984Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia.
Q42378526Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.
Q55453510Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients.
Q33416524Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia
Q60146450On statistical modeling of sequencing noise in high depth data to assess tumor evolution
Q86703719On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
Q47582687Optimizing frontline therapy of CLL based on clinical and biological factors.
Q38259446Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.
Q37410709Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment
Q92413642Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty
Q50852727Predicting time to first treatment in early stage CLL: scores, values and comparative prognostic models.
Q33714743Predicting treatment outcomes in CLL.
Q38997367Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia
Q47374141Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal
Q38691341Prognostic Factors for Chronic Lymphocytic Leukemia
Q87856666Prognostic Factors in the Era of Targeted Therapies in CLL
Q38680890Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?
Q38088354Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?
Q89637413Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Q96604441Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis
Q42962523Prognostic relevance of MYD88 mutations in CLL: the jury is still out.
Q92169106Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
Q30240258Prognostication of chronic lymphocytic leukemia in the era of new agents
Q49788400Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation
Q46318389Recent therapeutic advances in chronic lymphocytic leukemia
Q27853022Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Q47661367Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile
Q50025029Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in no
Q42378392SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis
Q52644149SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.
Q27852162SF3B1 mutations in chronic lymphocytic leukemia
Q33649977Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
Q38289057Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy
Q38187632Splicing factor mutations and cancer
Q59797087TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Q38177771TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia
Q61803940Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Q35146301Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting
Q36920426The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Q37035832The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Q37130881The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
Q55077967The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index
Q36715896The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection
Q52671466The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.
Q38826234The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.
Q47161072The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Q42711562The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
Q26749214The clinical implications of gene mutations in chronic lymphocytic leukaemia
Q38286344The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications
Q34710882The genomic landscape of chronic lymphocytic leukemia: clinical implications
Q44290485The impact of SF3B1 mutations in CLL on the DNA-damage response
Q36800105The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years
Q38748645The molecular pathogenesis of chronic lymphocytic leukaemia
Q49989104The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Q26865760The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy
Q30395427The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Q38132818Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.
Q34453174Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
Q42427620UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?
Q34016413Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
Q88195212Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
Q33817641Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia
Q88739450[Prognostic significance of CLL-IPI for Chinese patients with chronic lymphocytic leukemia]

Search more.